Albany Molecular Research Company Profile (NASDAQ:AMRI)

About Albany Molecular Research (NASDAQ:AMRI)

Albany Molecular Research logoAlbany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AMRI
  • CUSIP: N/A
  • Web: www.amriglobal.com
Capitalization:
  • Market Cap: $905.82 million
  • Outstanding Shares: 41,666,000
Average Prices:
  • 50 Day Moving Avg: $21.72
  • 200 Day Moving Avg: $18.41
  • 52 Week Range: $13.01 - $22.17
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 17.67
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $680.81 million
  • Price / Sales: 1.33
  • Book Value: $7.61 per share
  • Price / Book: 2.86
Profitability:
  • EBITDA: $73.33 million
  • Net Margins: -5.93%
  • Return on Equity: -13.39%
  • Return on Assets: -3.42%
Debt:
  • Debt-to-Equity Ratio: 0.62%
  • Current Ratio: 0.68%
  • Quick Ratio: 0.37%
Misc:
  • Average Volume: 1.27 million shs.
  • Beta: 1.15
  • Short Ratio: 8.49
 

Frequently Asked Questions for Albany Molecular Research (NASDAQ:AMRI)

What is Albany Molecular Research's stock symbol?

Albany Molecular Research trades on the NASDAQ under the ticker symbol "AMRI."

How were Albany Molecular Research's earnings last quarter?

Albany Molecular Research, Inc. (NASDAQ:AMRI) announced its quarterly earnings data on Tuesday, May, 10th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.21 by $0.14. The company had revenue of $102.80 million for the quarter, compared to the consensus estimate of $107.20 million. Albany Molecular Research had a negative net margin of 5.93% and a negative return on equity of 13.39%. View Albany Molecular Research's Earnings History.

Where is Albany Molecular Research's stock going? Where will Albany Molecular Research's stock price be in 2017?

4 brokerages have issued 1-year target prices for Albany Molecular Research's stock. Their predictions range from $18.00 to $18.00. On average, they expect Albany Molecular Research's share price to reach $18.00 in the next twelve months. View Analyst Ratings for Albany Molecular Research.

Who are some of Albany Molecular Research's key competitors?

Who are Albany Molecular Research's key executives?

Albany Molecular Research's management team includes the folowing people:

  • William S. Marth, President, Chief Executive Officer, Director
  • Felicia Ladin, Chief Financial Officer, Senior Vice President, Treasurer
  • Lori M. Henderson Esq., Senior Vice President, General Counsel, Secretary
  • Christopher M Conway, Senior Vice President - Discovery and Development and Global Commercial Sales
  • Milton Boyer, Senior Vice President - Drug Product Manufacturing
  • Steven R. Hagen Ph.D., Senior Vice President - Manufacturing and Pharmaceuticals
  • George Svokos, Chief Commercial Officer and Senior Vice President, API
  • Jimmy Wang Ph.D., Chief Information Officer
  • Thomas E. D' Ambra Ph.D., Non-Executive Chairman of the Board
  • David H. Deming, Director

How do I buy Albany Molecular Research stock?

Shares of Albany Molecular Research can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Albany Molecular Research's stock price today?

One share of Albany Molecular Research stock can currently be purchased for approximately $21.74.


MarketBeat Community Rating for Albany Molecular Research (NASDAQ AMRI)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  200
MarketBeat's community ratings are surveys of what our community members think about Albany Molecular Research and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Albany Molecular Research (NASDAQ:AMRI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $18.00 (17.20% downside)
Consensus Price Target History for Albany Molecular Research (NASDAQ:AMRI)
Price Target History for Albany Molecular Research (NASDAQ:AMRI)
Analysts' Ratings History for Albany Molecular Research (NASDAQ:AMRI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/12/2017First AnalysisDowngradeOverweight -> Equal WeightLowView Rating Details
6/8/2017J P Morgan Chase & CoDowngradeOverweight -> NeutralLowView Rating Details
6/6/2017William BlairDowngradeOutperform -> Market PerformLowView Rating Details
5/11/2017Morgan StanleyDowngradeOverweight -> Equal Weight$18.00HighView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for Albany Molecular Research (NASDAQ:AMRI)
Earnings by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Earnings History by Quarter for Albany Molecular Research (NASDAQ AMRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017$0.12$0.13$161.43 million$163.80 millionViewListenView Earnings Details
2/21/2017Q416$0.48$0.34$221.30 million$191.30 millionViewListenView Earnings Details
11/8/2016Q316$0.13$0.17$160.75 million$151.70 millionViewListenView Earnings Details
5/10/2016Q1$0.21$0.07$107.20 million$102.80 millionViewListenView Earnings Details
2/17/2016Q415$0.36$0.40$133.40 million$126.40 millionViewListenView Earnings Details
11/5/2015Q315$0.11$0.11$95.15 million$101.40 millionViewListenView Earnings Details
8/4/2015Q215$0.18$0.19$85.00 million$85.20 millionViewListenView Earnings Details
5/5/2015Q115$0.15$0.20$81.50 million$75.10 millionViewN/AView Earnings Details
2/12/2015Q414$0.33$0.28$91.90 million$86.60 millionViewN/AView Earnings Details
11/5/2014Q3 2014$0.16($0.02)$71.00 million$62.47 millionViewN/AView Earnings Details
8/5/2014Q214$0.20$0.22$65.64 million$68.20 millionViewN/AView Earnings Details
5/6/2014Q114$0.23$0.16$62.19 million$51.00 millionViewN/AView Earnings Details
2/12/2014Q4$0.17$0.22ViewN/AView Earnings Details
11/6/2013Q313$0.11$0.13$62.10 million$53.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.12$50.00 million$59.30 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.10$0.23$53.70 million$59.40 millionViewN/AView Earnings Details
2/12/2013Q4 2012$0.09$0.17$56.49 million$59.10 millionViewN/AView Earnings Details
8/1/2012$0.02$0.01ViewN/AView Earnings Details
5/9/2012$0.05$0.02ViewN/AView Earnings Details
2/7/2012($0.12)($0.19)ViewN/AView Earnings Details
11/8/2011($0.05)($0.19)ViewN/AView Earnings Details
8/8/2011($0.03)($0.02)ViewN/AView Earnings Details
5/4/2011($0.14)($0.02)ViewN/AView Earnings Details
2/7/2011($0.15)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Albany Molecular Research (NASDAQ:AMRI)
2017 EPS Consensus Estimate: $1.02
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.11$0.11$0.11
Q2 20172$0.23$0.28$0.26
Q3 20172$0.15$0.19$0.17
Q4 20172$0.42$0.54$0.48
Q1 20181$0.22$0.22$0.22
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Albany Molecular Research (NASDAQ:AMRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Albany Molecular Research (NASDAQ:AMRI)
Insider Ownership Percentage: 14.50%
Institutional Ownership Percentage: 72.10%
Insider Trades by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Institutional Ownership by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Insider Trades by Quarter for Albany Molecular Research (NASDAQ:AMRI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016Anthony J MaddalunaDirectorBuy1,518$16.46$24,986.28View SEC Filing  
11/30/2016Steven R HagenSVPSell9,000$16.71$150,390.00View SEC Filing  
11/16/2016Lori M HendersonSVPSell6,000$17.00$102,000.00View SEC Filing  
11/10/2016Steven R HagenSVPSell785$16.79$13,180.15View SEC Filing  
8/9/2016Steven R HagenSVPSell1,401$15.29$21,421.29View SEC Filing  
5/31/2016Kevin OconnorDirectorSell5,000$14.41$72,050.00View SEC Filing  
5/16/2016William S MarthCEOBuy12,500$12.86$160,750.00View SEC Filing  
5/13/2016George SvokosCOOBuy12,500$12.82$160,250.00View SEC Filing  
5/13/2016Steven R HagenSVPSell2,361$12.77$30,149.97View SEC Filing  
11/9/2015Ambra Constance M DMajor ShareholderSell50,000$19.60$980,000.00View SEC Filing  
8/17/2015Steven R HagenSVPSell1,000$20.45$20,450.00View SEC Filing  
6/10/2015Ambra Constance M DMajor ShareholderSell20,000$19.77$395,400.00View SEC Filing  
6/8/2015Steven R HagenSVPSell5,000$19.99$99,950.00View SEC Filing  
6/4/2015William S MarthCEOBuy10,000$19.98$199,800.00View SEC Filing  
6/1/2015Stuart M CableMajor ShareholderSell30,000$19.69$590,700.00View SEC Filing  
5/11/2015Ambra Constance M DMajor ShareholderSell20,000$19.11$382,200.00View SEC Filing  
5/8/2015Steven R HagenSVPSell14,500$19.27$279,415.00View SEC Filing  
4/10/2015Ambra Constance M DMajor ShareholderSell20,000$18.50$370,000.00View SEC Filing  
3/17/2015Steven R HagenSVPSell3,500$18.53$64,855.00View SEC Filing  
3/12/2015Kevin OconnorDirectorSell5,000$18.22$91,100.00View SEC Filing  
3/10/2015Ambra Thomas E Phd DDirectorSell20,000$17.65$353,000.00View SEC Filing  
3/10/2015George SvokosInsiderBuy10,000$17.72$177,200.00View SEC Filing  
3/5/2015William S MarthCEOBuy20,000$17.70$354,000.00View SEC Filing  
3/2/2015Stuart M CableMajor ShareholderSell30,000$16.39$491,700.00View SEC Filing  
2/10/2015Ambra Thomas E Phd DDirectorSell20,000$16.91$338,200.00View SEC Filing  
2/2/2015Stuart M CableMajor ShareholderSell30,000$16.32$489,600.00View SEC Filing  
1/12/2015Ambra Thomas E Phd DDirectorSell20,000$16.45$329,000.00View SEC Filing  
1/7/2015Stuart M CableMajor ShareholderSell7,694$16.00$123,104.00View SEC Filing  
1/5/2015Stuart M CableMajor ShareholderSell22,306$16.21$361,580.26View SEC Filing  
12/10/2014Ambra Constance M DMajor ShareholderSell20,000$16.24$324,800.00View SEC Filing  
12/5/2014Stuart M CableMajor ShareholderSell13,307$16.00$212,912.00View SEC Filing  
12/4/2014Stuart M CableMajor ShareholderSell16,693$16.00$267,088.00View SEC Filing  
11/10/2014William S MarthCEOBuy30,000$17.01$510,300.00View SEC Filing  
10/10/2014Ambra Constance M DMajor ShareholderSell20,000$21.62$432,400.00View SEC Filing  
10/1/2014Lori M HendersonSVPSell1,000$21.48$21,480.00View SEC Filing  
10/1/2014Stuart M CableMajor ShareholderSell30,000$21.61$648,300.00View SEC Filing  
9/10/2014Ambra Constance M DMajor ShareholderSell20,000$20.12$402,400.00View SEC Filing  
9/2/2014Lori M HendersonSVPSell2,500$19.56$48,900.00View SEC Filing  
8/28/2014Steven R HagenSVPSell1,250$19.74$24,675.00View SEC Filing  
8/14/2014Michael M NolanCFOSell10,000$19.76$197,600.00View SEC Filing  
8/12/2014Lori M HendersonSVPSell30,000$19.05$571,500.00View SEC Filing  
8/11/2014Ambra Thomas E Phd DDirectorSell20,000$18.99$379,800.00View SEC Filing  
8/8/2014Steven R HagenSVPSell10,797$18.99$205,035.03View SEC Filing  
8/1/2014Lori M HendersonSVPSell2,500$18.56$46,400.00View SEC Filing  
8/1/2014Stuart M CableMajor ShareholderSell30,000$18.69$560,700.00View SEC Filing  
7/10/2014Ambra Thomas E Phd DDirectorSell20,000$20.94$418,800.00View SEC Filing  
7/1/2014Lori M HendersonSVPSell2,500$20.62$51,550.00View SEC Filing  
7/1/2014Stuart M CableMajor ShareholderSell30,000$21.00$630,000.00View SEC Filing  
6/3/2014Steven R HagenSVPSell2,500$16.93$42,325.00View SEC Filing  
5/16/2014Steven HagenSVPSell1,250$15.45$19,312.50View SEC Filing  
5/15/2014George SvokosSVPBuy10,000$15.60$156,000.00View SEC Filing  
5/12/2014Steven HagenSVPSell5,897$15.00$88,455.00View SEC Filing  
5/12/2014William MarthCEOBuy30,000$15.40$462,000.00View SEC Filing  
5/1/2014Lori HendersonVPSell2,500$15.73$39,325.00View SEC Filing  
5/1/2014Stuart Cablemajor shareholderSell30,000$15.98$479,400.00View SEC Filing  
4/1/2014Lori HendersonVPSell2,500$18.74$46,850.00View SEC Filing  
4/1/2014Stuart Cablemajor shareholderSell30,000$18.52$555,600.00View SEC Filing  
2/27/2014Arthur RothDirectorSell5,000$15.95$79,750.00View SEC Filing  
2/27/2014Steven HagenSVPSell3,000$15.73$47,190.00View SEC Filing  
2/25/2014Steven HagenSVPSell2,500$15.19$37,975.00View SEC Filing  
2/24/2014Michael NolanCFOSell15,000$15.00$225,000.00View SEC Filing  
2/21/2014Steven HagenSVPSell1,500$14.87$22,305.00View SEC Filing  
2/19/2014Steven HagenSVPSell1,500$13.37$20,055.00View SEC Filing  
2/13/2014Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
12/4/2013Steven HagenSVPSell2,500$10.93$27,325.00View SEC Filing  
12/3/2013William MarthDirectorBuy30,000$10.75$322,500.00View SEC Filing  
11/22/2013Steven HagenSVPSell2,300$11.55$26,565.00View SEC Filing  
11/22/2013William MarthDirectorBuy20,000$11.57$231,400.00View SEC Filing  
9/13/2013Stuart Cablemajor shareholderSell30,000$12.00$360,000.00View SEC Filing  
8/1/2013Stuart M CableMajor ShareholderSell30,000$12.53$375,900.00View SEC Filing  
7/1/2013Stuart M CableMajor ShareholderSell30,000$12.47$374,100.00View SEC Filing  
6/12/2013Stuart M CableMajor ShareholderSell30,000$12.00$360,000.00View SEC Filing  
5/22/2013Bruce J SargentSVPSell7,500$10.97$82,275.00View SEC Filing  
5/10/2013Steven R HagenSVPSell1,200$10.40$12,480.00View SEC Filing  
12/3/2012William S MarthDirectorBuy10,000$5.00$50,000.00View SEC Filing  
11/15/2012Ambra Thomas E Phd DCEOBuy10,000$3.80$38,000.00View SEC Filing  
8/9/2012Steven R HagenVPSell3,000$3.00$9,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Albany Molecular Research (NASDAQ:AMRI)
Latest Headlines for Albany Molecular Research (NASDAQ:AMRI)
Source:
Loading headlines, please wait.

Social

Chart

Albany Molecular Research (AMRI) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.